Sagimet’s denifanstat enters Phase III trials for MASH treatment
The Phase III programme is expected to begin by the end of 2024 and is aiming to include a minimum of 1,800 patients.
30 October 2024
30 October 2024
The Phase III programme is expected to begin by the end of 2024 and is aiming to include a minimum of 1,800 patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.